CompletedNCT03943537
Intranasal Insulin and Brain Energy Use in Psychosis
About this title
Read the official source — NCT03943537Medication studyAges 18–40United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 40 years.
- Listed locations
- BelmontSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: October 1, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 87
- Sponsor
- Mclean Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 40 Years
- Official registry ID
- NCT03943537
- Official title
Show the full official title
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Belmont
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Mclean Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Intranasal Insulin.
Who was this study for?
Listed age limits: 18 years to 40 years.
